Decreasing Expression of Cancer-Driving Genes with CDK7
SY-1365 is a first-in-class selective, small molecule inhibitor of the cyclin-dependent kinase 7 (CDK7) that is in a Phase 1 clinical trial as a single agent and in combination with standard-of-care therapies in multiple patient populations with ovarian and breast cancers.
SY-1365 represents a new approach to treating cancer that we believe has potential in a range of difficult-to-treat solid tumors and blood cancers. Data from the completed dose escalation portion of the Phase 1 study of SY-1365 showed biological activity, as well as early signs of clinical activity, at tolerable doses in patients with advanced solid tumors. In preclinical studies, SY-1365 has demonstrated robust anti-tumor activity in models of a range of difficult-to-treat cancers, including those that fail to respond or have become resistant to existing therapies. SY-1365 has also been shown preclinically to preferentially kill cancer cells over non-cancerous cells and lower the expression of key cancer-driving genes.